Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 06:05 ET | Source: ProKidney

ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease

WINSTON-SALEM, N.C., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
October 14, 2022 12:00 ET | Source: ProKidney

ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022

- Company will present five posters discussing REACT and chronic kidney disease during the ASN Annual Meeting, November 3 - 6, 2022 - Investor and analyst scientific briefing to be hosted in...
September 23, 2022 06:15 ET | Source: ProKidney

ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
September 08, 2022 06:05 ET | Source: ProKidney

ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease...
August 31, 2022 06:05 ET | Source: ProKidney

ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations

Brings nearly 20 years of investor relations and corporate communications experience to ProKidney WINSTON-SALEM, N. C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)...
August 11, 2022 17:30 ET | Source: ProKidney

ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update

WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III or “SCS”) (Nasdaq: PROK) (the “Company”), a leading late clinical-stage...
August 11, 2022 10:01 ET | Source: ProKidney

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare...
July 20, 2022 08:00 ET | Source: ProKidney

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

WINSTON-SALEM, NC, July 20, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on Chronic...
July 12, 2022 08:00 ET | Source: ProKidney

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund...
June 23, 2022 08:00 ET | Source: ProKidney

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and...